How I Score Capital Allocation
The first version of this score had a pretty obvious problem: I was grading Meta and Amprius like management had the same job.
Meta can fund absurd projects from an already absurd cash engine. Amprius has a much narrower problem: scarce capital has to buy enough proof before the next financing happens on somebody else’s terms.
Those are obviously not the same job.
So I split the score in two. Same 10 points, completely different question.
Before I score anything, I figure out which problem management actually has
I use two capital-allocation scorecards.
| Company type | The real question |
|---|---|
| Compounder | What does management do with durable, internally generated cash? |
| Asymmetry | Does scarce capital buy enough thesis progress while keeping financing and downside risk survivable? |
The label follows the job management actually has, not whether the company happens to be called tech, industrial or whatever.
An asymmetry company does not have to be pre-revenue. It could be a commercialization story, a fast-scaling small company or a leveraged recovery. If financing, sequencing and downside containment can decide the per-share outcome, I want the asymmetry rubric.
If the business is already durable and self-funding, I want the compounder rubric.
The scores are stage-relative. A 7.5/10 asymmetry score and a 7.5/10 compounder score are not saying the same thing.
If I am not sure which rubric fits, I ask a simpler question: what can management screw up? If the main danger is wasting a huge stream of internally generated cash, compounder. If financing, dilution or badly sequenced spending can decide whether existing shareholders ever see the upside, asymmetry.
I do not want the decimal point doing fake precision for me
The score exists to force me to make a judgment. It is not there so I can put decimals in a table and pretend I discovered physics.
The main anchors move in 0.5-point steps. If the evidence genuinely sits between two anchors, I can use a 0.25-point step.
That is the limit.
So 0.75 means “clearly better than 0.5, not good enough for 1.0.” If I find myself debating 0.7 versus 0.8, I have already taken the score too seriously.
A few things keep me from taking the score more seriously than it deserves:
- Score the decision using the information management had at the time. A buyback that later looks awful was not automatically irrational when it happened.
- Outcomes still matter. Good intentions stop earning credit if the spending keeps producing bad economics.
- I try not to double-count the same fact. A cash pile can help the financing score; it does not magically make management strategically focused too.
- Missing evidence caps the score. “We think this will earn a great return” is not the same thing as showing one.
- For every category, I write down what would earn the next quarter-point or half-point.
That last one is probably the most useful. The exact number matters less to me than knowing what evidence would actually make it move.
Compounder rubric — 10 points
For a mature, self-funding business, I care about five things.
| Category | Max | What earns the points |
|---|---|---|
| Reinvestment quality | 3 | Organic spending earns attractive returns and strengthens the moat |
| Balance sheet / financing | 2 | Debt and liquidity match the durability of the cash flows |
| Capital deployment | 2 | Buybacks, dividends and M&A create more value than they destroy |
| Strategic focus | 2 | Management can say no and understands opportunity cost |
| Shareholder alignment | 1 | Dilution, incentives and compensation respect the cost of equity |
1. Reinvestment quality — 3 points
Start here. If this part is bad, the rest of the score can only do so much.
If a great business can keep putting retained cash back into itself at high returns, life gets pretty easy. If it cannot, I care a lot less about how beautiful the historical margins were.
I am looking for evidence that the spending is actually working: new products customers pay for, capacity that earns attractive returns, R&D that widens the moat, or new markets that improve earnings power rather than merely making the company larger.
“Capex is up 40%” tells me exactly one thing: capex is up 40%. It does not tell me the money is earning anything.
| Score | What it means |
|---|---|
| 0 / 3 | Reinvestment is clearly destroying value. Management keeps funding projects with poor economics or no plausible path to earning the cost of capital. |
| 0.5 / 3 | A few projects may work, but the overall record is weak and the payoff from the spending is hard to see. |
| 1.0 / 3 | Mixed. Some spending works, some does not, and retained earnings are not reliably creating value yet. |
| 1.5 / 3 | Adequate. Reinvestment is enough to maintain the franchise, but I do not see a strong incremental-return engine. |
| 2.0 / 3 | Good. Organic spending is producing visible growth or economic improvement beyond simple maintenance. |
| 2.5 / 3 | Very good. There is repeated evidence that incremental dollars produce attractive returns and strengthen the competitive position. |
| 3.0 / 3 | Exceptional. Management can deploy a lot of capital at high incremental returns for a long time, and the evidence keeps showing up in the business. |
The jump from 2.5 to 3 is supposed to be annoying. A company can be fantastic and still have a giant new spending wave that has not earned the benefit of the doubt yet.
2. Balance sheet / financing — 2 points
Debt does not lose points just for having the audacity to exist.
I care about whether the capital structure gives management choices or takes them away. Can the company keep investing through a downturn? Are maturities sensible? Does leverage become the strategy when things get ugly?
A fortress balance sheet is useful because it gives management choices. A giant pile of cash sitting there forever is not automatically evidence of genius.
| Score | What it means |
|---|---|
| 0 / 2 | The capital structure itself threatens equity value. Refinancing, covenant or liquidity risk can dictate strategy. |
| 0.5 / 2 | Aggressive. The business can probably carry the debt, but leverage meaningfully reduces flexibility and a downturn could force bad decisions. |
| 1.0 / 2 | Manageable. Financing is not broken, but debt, maturities or liquidity still constrain what management can do. |
| 1.5 / 2 | Strong. Leverage and liquidity fit the business, maturities are sensible, and management still has room to act. |
| 2.0 / 2 | Strategic asset. Financing risk is minimal and the balance sheet gives management real optionality. |
There is no universal “good” leverage ratio here. A payment network and a memory manufacturer should not be financed the same way.
3. Capital deployment — 2 points
This is where buybacks tend to get way too much free applause.
“Returned $10 billion to shareholders” sounds lovely in a press release. It tells me almost nothing until I know what price they paid and what else the cash could have done.
Once the good internal projects are funded, management has to choose among buybacks, dividends, acquisitions, debt reduction and patience. The action itself does not earn points. The economics do.
| Score | What it means |
|---|---|
| 0 / 2 | Repeated value destruction: overpriced M&A, terrible buybacks, unnecessary leverage or distributions that crowd out clearly better uses of capital. |
| 0.5 / 2 | Weak. There are some sensible decisions, but enough poor pricing or empire building that I do not trust the excess-cash allocation. |
| 1.0 / 2 | Neutral / mixed. Management mostly avoids disasters, but the deployment record is not an obvious source of per-share value. |
| 1.5 / 2 | Good. Most excess-cash decisions are valuation-aware and sensible, with only occasional decisions I would argue with. |
| 2.0 / 2 | Excellent. Management repeatedly chooses the best use among buybacks, M&A, debt reduction, dividends and doing absolutely nothing. |
This is also where hindsight can make me stupid. I want to judge whether the decision was rational with the information and price management had then, and then use the later outcome as evidence about the process. Different question.
4. Strategic focus — 2 points
A company with a ridiculous amount of cash can fund nonsense for an impressively long time.
This category is basically: can management stop itself?
I want capital going toward a coherent set of priorities that actually match the company’s advantages. I also want evidence that weak projects get killed, acquisitions need a reason beyond “growth,” and a large cash balance does not create an irresistible urge to invent another business.
| Score | What it means |
|---|---|
| 0 / 2 | Strategy is scattered or empire-building. Capital routinely flows into areas with little connection to the core advantage. |
| 0.5 / 2 | Weak focus. Too many projects, markets or acquisitions compete for attention and management rarely kills anything. |
| 1.0 / 2 | Mixed. The core strategy is understandable, but there is meaningful sprawl or a history of sticking with mediocre projects too long. |
| 1.5 / 2 | Focused. Most capital goes toward a coherent set of priorities and management shows a real willingness to redirect spending. |
| 2.0 / 2 | Ruthless focus. Management understands opportunity cost, concentrates capital where the company has an advantage and kills weak uses before the market has to force it. |
Great cash generation can hide bad discipline for years. I would rather notice the side quests before the income statement eventually makes them obvious.
5. Shareholder alignment — 1 point
Only one point. Still not decorative.
I care about whether buybacks actually reduce the diluted share count, whether stock-based compensation quietly eats the repurchases, how incentives are designed, and whether management behaves like issuing another share has a real cost.
| Score | What it means |
|---|---|
| 0 / 1 | Management treats the equity like free money. Dilution, compensation or incentives consistently work against existing owners. |
| 0.5 / 1 | Acceptable but leaky. Incentives are broadly reasonable, yet dilution or compensation offsets some of the value creation. |
| 1.0 / 1 | Strong alignment. Incentives emphasize per-share outcomes, dilution is controlled and management behaves like the existing share count belongs to real owners. |
For a mature compounder, alignment matters. It just does not get to outrank whether the company can actually do something useful with the cash in the first place.
Worked compounder example — Meta
Meta is basically why I wanted this rubric to exist.
The business can be incredible while the capital-allocation score is merely okay. That is much more useful to me than picking some perfect company, giving everything an 8 or 9 and congratulating myself for agreeing with the stock chart.
In Q2 2026, Meta reported $60.8B of revenue, up 28% year over year. Ad impressions rose 14% and average price per ad rose 12%. At the same time, operating margin fell to 31% from 43%, capex plus finance leases reached $31.1B in one quarter, and free cash flow was only $0.8B after the infrastructure build. The ad machine is getting stronger while management is simultaneously spending at a scale that deserves a very large question mark. Q2 2026 results
| Compounder category | Score | My read |
|---|---|---|
| Reinvestment quality | 2.5 / 3 | The ad engine and AI monetization are producing real evidence; the newest infrastructure wave still has to earn its return |
| Balance sheet / financing | 2.0 / 2 | Financing is not constraining the strategy |
| Capital deployment | 0.75 / 2 | The record is mixed enough that I do not treat excess-capital deployment as a strength |
| Strategic focus | 0.75 / 2 | Core AI spending fits the moat; Reality Labs is a very expensive competing priority |
| Shareholder alignment | 0.5 / 1 | Acceptable, but not clean enough for full credit |
| Total | 6.5 / 10 | Great cash generation. Management has expensive hobbies. |
The useful bit is that I still own Meta.
That is intentional. This score is not “do I like the company?” and definitely not “should I buy the stock?” It answers one narrower question: is management helping the value creation, or leaking some of it along the way?
Why Meta lands on each line
Reinvestment quality gets 2.5 / 3. The ad machine is giving me real evidence: revenue, impressions and pricing are all strong. I stop at 2.5 because the newest AI/data-center build is enormous and the return on that marginal infrastructure dollar still has to show up. I am not awarding the point because the capex slide looks ambitious.
Balance sheet / financing gets 2.0 / 2. Meta is not waiting on lenders or an equity window to fund the build. The existing business gives management the freedom to make these bets without putting the company in financial danger.
Capital deployment gets 0.75 / 2. Nothing here looks like a balance-sheet catastrophe. I also do not think the excess-cash record deserves to be called a strength. Being able to afford a long-duration bet does not make the opportunity cost disappear.
Strategic focus also gets 0.75 / 2, but for a different reason. AI spending directly supports the engagement and advertising moat. Reality Labs is a separate platform bet consuming enormous resources. Meta knows exactly what its current cash engine is; management is still willing to fund another future alongside it.
Shareholder alignment gets 0.5 / 1. Existing owners participate in an incredible cash-generating business, but I am not giving full credit while management retains this much discretion to fund uncertain long-duration projects.
That split is exactly why I want the categories visible. 2.5 / 3 on reinvestment says the core machine is working. 0.75 / 2 on focus says management can still take a fantastic business and find a lower-return place to send the cash.
Asymmetry rubric — 10 points
Now take the exact same idea and move to a company with almost none of Meta’s financial luxury.
A young or fragile business does not get bonus points for cosplaying as a mature one. Paying a dividend would be idiotic if that cash is what gets the company to the next customer, qualification or financing point.
For these companies, the capital structure gets a much bigger vote.
| Category | Max | What earns the points |
|---|---|---|
| Thesis progress / reinvestment | 3 | Spending turns into measurable technical, commercial, operating or recovery proof |
| Runway / financing discipline | 3 | Cash, leverage and financing give the thesis enough time without reckless dilution or balance-sheet stress |
| Capital sequencing | 2 | Expansion, deleveraging and capacity follow evidence instead of getting ahead of it |
| Strategic focus | 1 | Scarce resources stay concentrated on the milestones that matter |
| Shareholder protection | 1 | Dilution, warrants and SBC are treated as real economic costs |
Financing gets three points because a genuinely amazing product can still become a terrible stock if existing shareholders have to keep financing the journey on awful terms.
1. Thesis progress / reinvestment — 3 points
A giant TAM slide or a wall of customer logos does not earn much by itself. I want to see what the money actually bought.
That is basically the question for me: what did the last dollar buy?
Depending on the company, that might be revenue, gross-margin improvement, manufacturing yield, a customer qualification, contracted backlog turning into shipments, repeat orders, a technical milestone, deleveraging or the first real move toward positive EBITDA / free cash flow.
| Score | What it means |
|---|---|
| 0 / 3 | Capital is being consumed without meaningful thesis progress, or the evidence is actively moving the wrong way. |
| 0.5 / 3 | Mostly story. There may be technical promise or early interest, but spending has produced very little independent commercial or operating proof. |
| 1.0 / 3 | Early proof exists, but it is fragile: a pilot, first customer, first qualification, early revenue or one good quarter. |
| 1.5 / 3 | Real milestones are being hit. The thesis is less speculative than before, but the evidence is not repeatable enough yet. |
| 2.0 / 3 | Repeated operating proof. Revenue, margins, customers, technical milestones or cash economics are moving in the direction the thesis requires. |
| 2.5 / 3 | Strong conversion of capital into evidence. Multiple independent milestones are improving and the business is clearly de-risking. |
| 3.0 / 3 | Exceptional. Each round of spending materially increases the probability and value of the thesis, with repeatable commercial economics rather than one-off wins. |
The difference between 2.5 and 3 is usually repeatability. One great stretch is nice. I want an engine.
2. Runway / financing discipline — 3 points
This category can basically veto the rest of the score.
I do not really care that management says it has 18 months of runway if the thing that matters is 24 months away. I map cash to the next thesis milestone, then ask:
Does the company control the timing of the next financing, or does the market?
Cash, burn, debt maturities, covenants, warrants, ATM usage and financing terms all matter. So does non-dilutive capital from customers, governments or partners. Raising money is not automatically a problem. What I care about is whether enough proof shows up before the next raise that the company has some negotiating power when it gets there.
| Score | What it means |
|---|---|
| 0 / 3 | Financing is an immediate threat to the thesis. The company may not reach the next important milestone without emergency capital, restructuring or highly punitive terms. |
| 0.5 / 3 | Very weak. Runway is short relative to the work left, leverage is dangerous, or the next financing likely happens from a position of weakness. |
| 1.0 / 3 | Fragile. The company can keep operating, but a meaningful raise or refinancing is likely before enough thesis proof exists to improve the terms. |
| 1.5 / 3 | Adequate. There is enough capital to reach at least one important milestone, but another financing is still part of the base case. |
| 2.0 / 3 | Good. The balance sheet should fund multiple meaningful milestones, and management has reasonable flexibility over when and how to finance. |
| 2.5 / 3 | Very good. The company has a credible path to breakeven, self-funding or a much stronger negotiating position before it needs more equity. |
| 3.0 / 3 | Exceptional for the stage. The thesis can reach its major de-risking point without depending on punitive external capital, and the balance sheet provides real optionality. |
A leveraged recovery can fail this test too. The mechanism is different, but the result is the same: too much debt can absorb the operating improvement before equity owners ever see it.
3. Capital sequencing — 2 points
The order matters a lot more than the headline size of the investment.
For a commercialization story, I usually want:
customer evidence → capacity → more evidence → more capacity
For a leveraged recovery:
operating repair → deleveraging → optionality → buybacks / expansion
The version that makes me nervous is:
hope → giant capital commitment → please let the thesis catch up
That is usually where an operating thesis starts turning into a financing thesis.
| Score | What it means |
|---|---|
| 0 / 2 | Management is committing large, hard-to-reverse capital before the thesis has earned it. One bad assumption can strand the balance sheet. |
| 0.5 / 2 | Spending is materially ahead of evidence. There are some gates, but capacity, acquisitions or expansion still rely heavily on optimistic demand assumptions. |
| 1.0 / 2 | Mixed. Some capital is staged intelligently, while other spending gets ahead of proof or competes with a more urgent balance-sheet use. |
| 1.5 / 2 | Disciplined. Most major commitments follow real milestones, and management preserves the ability to change course. |
| 2.0 / 2 | Excellent sequencing. Capital is released in stages as technical, customer and economic evidence improves. |
A company can be hitting milestones and still finance the next factory too early. That is why this category is separate from thesis progress.
4. Strategic focus — 1 point
Scarce capital really hates side quests.
I usually try to name the two or three things the company really has to prove next, then see whether the spending map looks anything like those priorities.
| Score | What it means |
|---|---|
| 0 / 1 | Capital is scattered across too many products, markets, acquisitions or side bets for the company’s resources. |
| 0.5 / 1 | The core priority is visible, but management still spreads meaningful resources across projects that can distract from the main thesis. |
| 1.0 / 1 | Scarce capital is concentrated on the milestones that actually change the probability of success. |
A turnaround chasing acquisitions before fixing the core business gets the same skeptical look as a tiny technology company trying to attack six markets at once.
5. Shareholder protection — 1 point
Dilution is not a moral failure. Bad dilution absolutely is.
If issuing shares at a fair price gets the company through a major milestone and materially raises the value of every remaining share, fine. What matters is what the old owners got for the new shares.
I track basic and diluted share-count growth, warrants, convertibles, stock-based compensation, ATM / follow-on issuance and the actual terms of any raise.
| Score | What it means |
|---|---|
| 0 / 1 | Existing owners are the financing source of last resort. Dilution, warrants or financing terms can overwhelm the operating progress. |
| 0.5 / 1 | Real leakage exists, but the dilution is understandable for the stage and the capital raised is producing enough progress that I cannot call it destructive. |
| 1.0 / 1 | Strong protection. Management minimizes unnecessary dilution, raises equity from a position of strength when possible and treats every new share as a real economic cost. |
The useful question is not “did the share count rise?” It is: what did the new shares buy for the old shareholders?
Worked asymmetry example — Amprius
Amprius is almost the mirror image of Meta, which is why the same rubric would be ridiculous.
The dollars are tiny next to Meta, but financing matters much more. One weak capital decision can change who actually owns the upside before the battery thesis gets fully proven.
In Q2 2026, revenue reached $34.0M, up 126% year over year, gross margin reached 27%, and management raised FY2026 guidance to at least $140M of revenue while targeting at least $4M of adjusted EBITDA and less than $10M of capex. That is exactly what I want scarce capital buying: more revenue, better margins and a path toward self-funding without immediately setting money on fire with a giant factory bill. Q2 2026 results
Then I get to the balance sheet, where the story becomes less comfortable. At June 30, 2026 Amprius had $74.5M of cash and no debt, and management said that was enough for at least the next twelve months. It also said additional financing may be needed. Shares outstanding increased from about 134.5M at year-end 2025 to 146.1M by June 30, 2026, roughly 8.6%. Some of that came through option/RSU activity and a warrant exchange. Q2 2026 10-Q
So the score lands here:
| Asymmetry category | Score | My read |
|---|---|---|
| Thesis progress / reinvestment | 2.5 / 3 | Revenue and margins are finally turning the battery story into operating evidence |
| Runway / financing discipline | 2.0 / 3 | Cash and no debt help; another financing is still plausible |
| Capital sequencing | 1.5 / 2 | FY2026 capex under $10M is disciplined; future commercial scale can still become expensive |
| Strategic focus | 1.0 / 1 | Weight-sensitive aviation, drones and mobility remain a coherent place to spend the money |
| Shareholder protection | 0.5 / 1 | Dilution is already visible enough that I refuse to hand-wave it |
| Total | 7.5 / 10 | Solid for this stage. The financing risk is still very much alive. |
Why Amprius lands on each line
Thesis progress / reinvestment gets 2.5 / 3. Revenue, gross margin and the path toward positive adjusted EBITDA are no longer just technical promise; they are operating evidence. I do not give it 3 because repeatable commercial scale still needs more proof.
Runway / financing discipline gets 2.0 / 3. Cash and no debt put Amprius above the fragile middle of the rubric. It does not get 2.5 or 3 because another financing may still be needed before the commercialization path is self-funded.
Capital sequencing gets 1.5 / 2. Less than $10M of planned FY2026 capex while revenue scales is exactly the kind of staged spending I want. The missing half-point is what happens when commercial scale demands more capacity.
Strategic focus gets 1.0 / 1. The capital is aimed at markets where energy density actually matters. I do not see a bunch of unrelated side quests competing with the core milestones.
Shareholder protection gets 0.5 / 1. The share count has risen and the warrant exchange matters, so full credit would be silly. But the capital has also coincided with real operating progress. That is different from dilution that merely keeps the lights on.
And no, 7.5 > 6.5 does not mean Amprius is somehow a better capital allocator than Meta. The rubrics are stage-relative. Amprius is doing a solid job at the problem it actually has: buy enough proof without letting financing eat the thesis first.
The total can hide the thing that matters
This is where a neat 10-point total can become a little too neat.
For a compounder, reinvestment quality is the first line I look at. Great buybacks are not much consolation if the business keeps pouring money into low-return projects.
For an asymmetry company, I usually start with runway and financing discipline. Great technology or a giant backlog does not help much if the company loses its negotiating power before the next milestone.
I still calculate the total because it is useful. I just try not to let the addition hide the one category that can actually kill the thesis.
What the total is actually useful for
The scale is shared. The meaning is not.
| Score | Compounder | Asymmetry |
|---|---|---|
| 9–10 | Elite capital engine. Reinvestment and deployment are clearly adding per-share value. | Rare. Capital is buying proof quickly, the next milestones are well funded and shareholder leakage is limited. |
| 8–8.9 | Strong. Capital allocation is an asset even if I can still argue with individual decisions. | Strong for the stage. Thesis progress is real and financing / sequencing risk looks manageable. |
| 7–7.9 | Solid, but there is meaningful leakage or a real reinvestment / M&A / capex question to watch. | Solid for the stage. Progress is real, but at least one financing, sequencing or dilution risk is still open. |
| 6–6.9 | Mixed. Capital allocation deserves its own risk premium in the valuation. | Fragile. The business thesis can still work, but the capital structure or sequencing can spoil the per-share outcome. |
| <6 | Management is becoming part of the value-destruction case. | Financing, dilution or capital sequencing is becoming part of the bear case. |
The score is not a valuation and it is definitely not a tattoo. If the evidence changes, the score moves.
Where this actually sits in the research process
This comes after the valuation work. A good capital-allocation score does not magically make an expensive stock cheap.
My Bear / Base / Bull Playbook answers: what return am I underwriting from this price?
This Playbook answers: is management increasing or leaking the value I am underwriting?
A full Research Note only needs to carry the output:
- which rubric I used;
- the category scores;
- the biggest positive;
- the biggest capital risk.
The company page only needs the useful output from this. Re-teaching the whole framework every time would defeat the point of having a Playbook.
The question I actually care about
For a compounder:
Is management making the compounding machine stronger with each dollar?
For an asymmetry position:
Is each scarce dollar buying enough proof while keeping the path to the next dollar survivable?
If I finish the table and still cannot answer those questions in plain English, that is usually a sign the score looks more certain than I actually feel.